

## Nemucore Publishes Research Article on Development of Nanoemulsion for Ovarian Cancer

FOR IMMEDIATE RELEASE

[\*PRLog \(Press Release\)\*](#) - **Jun. 24, 2014 - WORCESTER, Mass.** -- Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced its publication in the journal *Drug Delivery* which supports the scientific rationale for Nemucore's ongoing NMI-500 program. The paper, titled "Formulation Development of a Novel Targeted Theranostic Nanoemulsion of Docetaxel to Overcome Multidrug Resistance in Ovarian Cancer" was co-authored by NMI's Niravkumar Patel, Joseph Cacaccio, and Timothy Coleman. Taxane based chemotherapy is a primary and secondary line of treatment for ovarian cancers. Despite these chemotherapeutics patients will eventually become resistant to treatment. NMI is designing a novel targeted nanomedicines to overcome limitations associated with treating multidrug resistant cancers. The study results demonstrate this novel nanomedicine that delivers docetaxel through folate receptor mediated endocytosis enhanced cytotoxicity of taxane against drug-resistant ovarian cancer cells.

Nemucore's lead compound is NMI-500, a personalized nanomedicine that targets ovarian cancer through the folate receptor, a cell-surface receptor overexpressed in many ovarian cancers. "These results are strong evidence for the importance of targeted nanomedicines to treat drug-resistant cancers," said Timothy Coleman, Ph.D. Nemucore's CEO "Furthermore, this data shows that importance of nanomedicines as the future of personalized medicines. The interesting physical properties of these nanomedicines can be exploited to overcome anatomical and physiological barriers associated in drug delivery to the complex diseases such as cancer."

### About Ovarian Cancer

In the U.S., approximately 80,000 women are diagnosed with some form of gynecological cancer (cervical, ovarian, uterine, vaginal, and vulvar) with approximately 27,000 deaths annually. Of these 80,000 gynecological cancers diagnosed annually, an estimated 22,000 new ovarian cancer cases are diagnosed alongside approximately 15,000 deaths in the U.S., making epithelial ovarian cancer the most lethal of gynecologic cancers.

### About Nemucore Medical Innovations, Inc.

NMI is dedicated to designing, investigating, developing, and commercializing life-saving novel nanomedicines for the treatment of ovarian cancer and other unmet medical needs. Ultimately, NMI's products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester, Massachusetts. For more information, please visit <http://www.nemucore.com>.

## **Forward-looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.